Getinge (GETI) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
18 Jul, 2025Executive summary
Achieved 4.1% organic net sales growth and 4.4% order intake growth in Q2, with positive development across all business areas and regions.
Margin improvements driven by acquisitions, pricing, and product mix, despite significant headwinds from tariffs and FX.
Financial position remains robust, with leverage well below internal thresholds and improved free cash flow.
Paragonix contributed positively to group margins and EBITA earlier than expected, supported by successful product launches.
Continued focus on recurring revenue, high-margin products, and quality improvements, with recurring revenue now at 65% of sales.
Financial highlights
Adjusted gross margin increased to 50.8% in Q2 2025 (up from 50.0%); adjusted gross profit reached SEK 4,183M.
Adjusted EBITA/EBITDA margin improved to 12.0%–14.2% year-over-year; adjusted EBITA reached SEK 989M.
Free cash flow was SEK 510M–0.5B in Q2, up 76% year-over-year, positively impacted by working capital changes.
Net debt/EBITDA at 1.4x–1.7x, well below the 2.5x target.
Currency effects and tariffs negatively impacted margins, with SEK 110M in tariff costs absorbed in Q2.
Outlook and guidance
2025 organic net sales growth expected in the range of 2% to 5%, unchanged from previous guidance.
Long-term target of at least 12% adjusted EPS CAGR for 2024–2028 reaffirmed, despite tariff and FX impacts.
No significant change in margin guidance; productivity improvements and cost mitigation expected to offset headwinds.
Management maintains a positive outlook for the remainder of 2025, despite elevated geopolitical risks.
Latest events from Getinge
- Strong sales and margin gains driven by Acute Care Therapies, with robust financial outlook.GETI
Q2 20243 Feb 2026 - Full-year organic sales up 4.9% with record Q4, resilient margins, and strong 2026 outlook.GETI
Q4 20252 Feb 2026 - Order intake up 10%, but margins and earnings pressured; 2024 growth outlook maintained.GETI
Q3 202419 Jan 2026 - Record sales and margin gains in Q4 2024, with strong outlook for 2025.GETI
Q4 20249 Jan 2026 - Double-digit sales and margin growth, low leverage, and a positive 2025 outlook despite uncertainties.GETI
Q1 202529 Nov 2025 - Q3 2025 saw robust organic growth and margin gains, despite tariff and currency pressures.GETI
Q3 202521 Oct 2025